Understand the source comparison
GHRP-6 Acetate Dosage Comparison Across Research Contexts
Low-Dose Chronic 2x daily 50–100mcg Long-term metabolic studies requiring minimal GH perturbation Mild appetite increase (10–15% caloric intake above baseline) Minimal growth hormone elevation; suitable for models where GH spike is a confounding variable Stand
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Low-Dose Chronic
- 2x daily
- 50–100mcg
- Long-term metabolic studies requiring minimal GH perturbation
- Mild appetite increase (10–15% caloric intake above baseline)
- Minimal growth hormone elevation; suitable for models where GH spike is a confounding variable
- Standard Appetite Protocol
- 2–3x daily
- 100–200mcg
- Appetite stimulation studies, cachexia models, caloric intake research
- Moderate to strong appetite increase (22–28% above baseline per meal)
- Optimal balance of appetite effect and protocol simplicity; aligns with natural ghrelin peaks
- High-Dose GH-Focused
- 1–2x daily
- 300–500mcg
- Growth hormone secretion studies where appetite is secondary endpoint
- Plateau appetite effect (25–31% above baseline); diminishing returns above 300mcg
- Receptor saturation limits appetite benefit; higher incidence of transient nausea and flushing
- Pulsatile Micro-Dose
- 4–5x daily
- 50mcg
- Circadian rhythm studies, ghrelin receptor dynamics research
- Sustained mild appetite elevation throughout waking hours
- Logistically complex; requires strict injection-timing discipline; used in specialised metabolic research
- Professional Assessment
- Twice-daily 150mcg is the most reproducible protocol for appetite-focused research. Strong ghrelin activation without receptor desensitisation, logistically feasible timing windows, and consistent food intake response across diverse research models.